Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib

The document reported a case of severe refractory scarring alopecia linked to the combined use of Ficlatuzumab (AV-299) and Gefitinib. The authors, Yi-Hsien Shih, Pin-Chun Chen, and Chia-Yu Chu, highlighted the potential adverse effects of this drug combination, emphasizing the need for careful monitoring in patients undergoing such treatments. The study underscored the importance of recognizing drug-induced alopecia as a significant side effect, which could impact patient quality of life and treatment adherence.